Critical Survey: NKGen Biotech (NYSE:NKGN) versus Alpha Cognition (OTC:ACOGF)

Alpha Cognition (OTC:ACOGF) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Alpha Cognition and NKGen Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	2	0	3.00
NKGen Biotech	0	0	0	0	0.00

Given Alpha Cognition’s stronger consensus rating and higher probable upside, analysts plainly believe Alpha Cognition is more favorable than NKGen Biotech.

Profitability

This table compares Alpha Cognition and NKGen Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-522.43%
NKGen Biotech	N/A	N/A	-479.36%

Earnings and Valuation

This table compares Alpha Cognition and NKGen Biotech”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	N/A	N/A	-$13.77 million	C($0.12)	N/A
NKGen Biotech	N/A	N/A	-$82.94 million	($1.72)	-0.03

NKGen Biotech is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Alpha Cognition has a beta of 2.8, meaning that its stock price is 180% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.

Institutional & Insider Ownership

76.2% of NKGen Biotech shares are held by institutional investors. 31.5% of Alpha Cognition shares are held by company insiders. Comparatively, 10.4% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Alpha Cognition beats NKGen Biotech on 7 of the 10 factors compared between the two stocks.

About Alpha Cognition

Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

About NKGen Biotech

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.